Reference: FDA. (2021). Vaccines and related biological products advisory committee meeting: February 26, 2021. Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. FDA Briefing Document. Summary: The FDA briefing document details the Emergency Use Authorization (EUA) request submitted by Janssen Biotech for the Ad26.COV2.S vaccine aimed at preventing COVID-19. This single-dose adenovirus vector vaccine demonstrated […]
Reference: Author. (2021). Case investigation form for AEFI serious, severe, cluster, AESI for all vaccines including COVID-19. Retrieved from [insert URL if available] Summary: The document is a Case Investigation Form designed to report Adverse Events Following Immunisation (AEFI) and Adverse Events of Special Interest (AESI) for all vaccines, including COVID-19. It is intended for
Reference: ProCon.org. (2021). FDA-approved prescription drugs later pulled from the market by the FDA. Retrieved from https://prescriptiondrugs.procon.org/fda-approved-prescription-drugs-later-pulled-from-the-market/ Summary: The article by ProCon.org discusses various prescription drugs that were once FDA-approved but later withdrawn from the market due to safety concerns. The FDA’s role in drug removal is highlighted, emphasising that drugs are typically pulled when
Reference: Law, B. (2020). Priority List of COVID-19 Adverse Events of Special Interest: Quarterly Update December 2020. Safety Platform for Emergency Vaccines (SPEAC). Summary: The report provides a quarterly update on the Safety Platform for Emergency Vaccines (SPEAC) regarding Adverse Events of Special Interest (AESI) related to COVID-19. The December 2020 update includes three new
Reference: Wu, Q., Dudley, M. Z., Chen, X., Bai, X., Dong, K., Zhuang, T., Salmon, D., & Yu, H. (2021). Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Medicine, 19, 173. https://doi.org/10.1186/s12916-021-02059-5 Summary: This article presents a rapid review and meta-analysis of the safety profiles of COVID-19 vaccines. It highlights public
Reference: Thomas, S. J., Moreira, E. D. Jr., Kitchin, N., et al. (2021). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine, 385, 1761-73. https://doi.org/10.1056/NEJMoa2110345 Summary: This supplementary appendix provides detailed data related to the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine, as explored in
Reference: Kirsch, S. (2021). All you need to know about COVID vaccine safety. COVID-19 Early Treatment Fund. Summary: Steve Kirsch, Executive Director of the COVID-19 Early Treatment Fund, argues that COVID vaccines may be responsible for more deaths than they prevent. He estimates over 150,000 excess deaths associated with the vaccines, contrasting this figure with
Reference: Liu, J., Wang, J., Xu, J., Xia, H., Wang, Y., Zhang, C., Chen, W., Zhang, H., Liu, Q., Zhu, R., Shi, Y., Shen, Z., Xing, Z., Gao, W., Zhou, L., Shao, J., Shi, J., Yang, X., Deng, Y., Wu, L., Lin, Q., Zheng, C., Zhu, W., Wang, C., Sun, Y. E., & Liu, Z.
Reference: Bruno, R., McCullough, P., et al. (2021). 157 Top Scientists and Doctors Release Shocking Study on COVID Vaccines and Demand Immediate Stop to All Vaccinations. Global Research. Summary: A report by 57 prominent scientists and doctors has raised significant concerns about the safety and efficacy of COVID-19 vaccines, urging an immediate cessation of vaccination
Reference: Informed Consent Action Network. (2022). V-safe data. https://icandecide.org/v-safe-data/#v-safe-downloads Summary: The V-Safe Data report from the Informed Consent Action Network (ICAN) presents comprehensive statistics on adverse health impacts following COVID-19 vaccinations. The data indicates that over 10 million individuals registered on the V-Safe platform, with significant health impacts reported, totalling approximately 6.4 million. The report